Close

What are ADC's

Our services

ADC Review
is made possible by:




NCT00723359 (Clinical Trial/ BT062 / Indatuximab ravtansine)

Study Title
Safety and Dose Determining Study of BT062 in Patients With Relapsed or Refractory Multiple Myeloma (NCT00723359)

Trial Description
This Phase I research study is to test the effects and best dose of BT062 (also known as Indatuximab ravtansine) in treating patients with relapsed or refractory multiple myeloma. This trial is sponsored by Biotest Pharmaceuticals Corporation. [1]

Study Data

  • Condition:Multiple Myeloma
  • Interventions:
    • Drugs used in this trial
      • BT062 (Indatuximab ravtansine)
  • Phase: I
  • Enrollment: 32
  • Start: August 2008
  • Completion: April 2012
  • Last verified: July 2013

Study Schematic 

(Coming soon)

Click here to Return to Drug map


Last Editorial review: September 29, 2015
Information based on ClinicalTrials.gov (NIH/NCI) and other sources.

Copyright © 2015 InPress Media Group. All rights reserved. Republication or redistribution of InPress Media Group content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group. InPress Media Group shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. ADC Review / Journal of Antibody-drug Conjugates is a registered trademarks and trademarks of InPress Media Group around the world.

Add to Flipboard Magazine.


Share

Recommended Articles

Four Ways to Show Nonobviousness of ADC Inventions

05 October, 2018

When the first antibody-drug conjugate (ADC) was approved by the U.S. Food and Drug Administration (FDA) in 2000,[1] only a handful of patent applications claiming ADCs had been published.[2] As research cont...


Skip to toolbar